Expression data from JQ1 (0.2 uM) treated tamoxifen-resistant MCF7 cells

ABSTRACT: Estrogen signaling pathway is critical for breast cancer development and has remained the major adjuvant therapeutic target for this disease. Tamoxifen has been used in clinic for many years to treat ER-positive breast cancer. However a great many (30%) suffer relapse due to drug resistance. In this study, the bromodomain inhibitor JQ1 was found to down-regulate ERalpha gene expression and have anti-tumor effect in cultured tamoxifen-resisant breast cancer cells. We used microarrays to detail the global programme of gene expression in tamoxifen-resistant MCF7 cells treated with the bromodomain inhibitor JQ1.

ORGANISM(S): Homo sapiens

PROVIDER: GSE49124 | GEO | 2014/03/01

SECONDARY ACCESSION(S): PRJNA213138

REPOSITORIES: GEO